Malignant Glioma Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H1 2018 - Product Image

Malignant Glioma Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H1 2018

  • ID: 4460442
  • Report
  • Region: Global
  • 205 Pages
  • VPA Research
1 of 4
This Research Analyzes the Evolution of Glioma Clinical Trial Trends Across Countries and Regions

Glioma clinical trials report provides comprehensive analysis and trends in global Glioma disease clinical trials. The research work analyzes the evolution of Glioma clinical trial trends across countries and regions.

The report focuses on drugs and therapies being evaluated for Glioma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Glioma clinical trials.

Major drugs under development in Glioma are provided in the report along with their details of mechanism of action, route of administration, target, therapy, molecule and class.

Scope of the Report:

  • Number of Glioma clinical trials across regions - Asia and Oceania, Europe, Middle East Africa and Americas
  •  Trial information by Phase and Subjects recruited
  •  Trial information by status, type, sponsor type
  •  Drugs used for treatment of Glioma
  •  Both observational and interventional trials analyzed
  •  Success rates of trials are analyzed
  •  Trends in enrollment over the past ten years identified
  •  Leading sponsors of Glioma clinical trials worldwide are listed

Reasons to Buy:

  •  Track competition and design competitive advantages
  •  Identify right partners to associate with for further research
  •  Evaluate potential opportunities available in further clinical trials of the disease
  •  Formulate business development strategies through success rates of clinical trials
  •  Identify quick markets for recruiting subjects based on trials count by each market

Glioma - The condition occurs when the glial cells in the brain are affected and account for around one -third of all brain tumors. On the basis of location, these are classified as supratentorial (above tentorium) and infratentorial (below tenotrium).

On the basis of pace of development, these are categorized as Low grade (grades 1 and 2) and high grade (3 and 4). Treatment options vary with the grade of the disease, but most often it includes a combination of medicine, surgery, radiation and chemo therapies.

Malignant Glioma - Malignant Glioma is the most regular subtypes of glioma condition occurring in patients aged between 60 and 80. The condition is classified as grade 3 and grade 4, which comprises anaplastic high -grade gliomas and glioblastomas respectively.

High Grade Glioma - Malignant or high -grade glioma tumors are categorized as Grade 3 and Grade 4. Of this Grade 3 tumor types include -

Anaplastic astrocytoma - The rare disease type comprises an estimated one -third of all astrocytoma types. Often observed in older persons, the condition can occur in any aged person. Astrocytoma emerges from star shaped cells in the brain, called astrocytes.

Anaplastic oligodendroglioma - It is a rare type of malignant tumor occurring mainly between 45 and 50 years of age. They possess abnormal genetic material and unique molecular, clinical, and histological characteristics and are important to diagnose.

Anaplastic oligoastrocytoma - Oligoastrocytoma occurs when either oligodendrocytes and astrocytes or both grow rapidly, causing formation of tumors in the brain. The term ‘Anaplastic’ refers to condition when tumor can spread into nearby tissues. They occur in Cerebrum area.

Anaplastic ependymoma - The fast growing subtype occurs primarily in posterior fossa part. The tumor cells show rapid growth pace and are associated with a less favorable prognosis and have higher possibility to infiltrate around the brain or disseminate into cerebrospinal fluid resulting in drop metastases.

Glioblastoma - The grade 4 type condition is further classified as primary and secondary types. The primary subtype occurs without earlier diagnosis of low grade tumors while the secondary type arouses from development of grade 2 or 3 subtypes. Tumor occurs as a result of accumulation of different mutations.

Pontine Gliomas - Diffuse intrinsic pontine glioma (DIPG) is an aggressive type of malignant glioma, arising from glioma tissue. As these are observed in the bottom area of the brain, they are tough to be treated. It is observed mostly in children.

Low Grade Glioma (LGGs) or often referred to as Grade -1 and 2 tumors, arouse from brain cells including astrocytes and oligodendrocytes. Causing mild and large seizures, the Glioma type is treated through a combination of surgery, chemotherapy, and radiation on the basis of disease condition. The condition is primarily observed in young and healthy individuals. Compared to high grade Glioma, these patients survive for long periods and lead quality life as this is a slow growth disease.

On the basis of appearance under microscope and genetic modifications, Low grade gliomas are classified as -
Pilocytic astrocytomas - Observed in adults aging less than 25 and progresses very slowly compared to other types

Diffuse astrocytomas - Most observed subtype of low -grade glioma. Late 30’s individuals are the most affected age. Type of modification in IDH isocitrate -dehydrogenase gene determines the sub -types of Diffuse astrocytomas.

Oligodendrogliomas - Slow growing tumors, having mutation in the IDH gene in terms of missing 1p and 19q chromosomes.

Gangliogliomas - Posesses both gliomas and tumor related characteristics.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

1 Table of Contents
1.1 List of Figures
1.2 List of Tables

2 Executive Summary
2.1 Report Guide

2.2 Key Findings
2.2.1 Overview of Global Clinical Trials Initiated in 2017
2.2.2 Average Enrolment by Country, 2010 - 2017
2.2.3 Prominent Companies in Global Malignant Glioma Trials, 2010 - 2017

3 Malignant Glioma Drugs in Ongoing and Completed Trials
3.1 Prominent Drugs in Development and Approved Stages for Malignant Glioma
3.2 Malignant Glioma Product Snapshots
3.2.1 Malignant Glioma Drug Profiles

4 Global Malignant Glioma Clinical Trial Research Trends
4.1 Clinical Trials by Top 10 Countries, 2010 - 2017
4.1.1 Clinical Trials by Country
4.1.2 Number of Ongoing/Planned Trial Locations in Each Country
4.2 Subjects Recruited by Top 10 Countries, 2010 - 2017
4.2.1 Total Enrolment by Country
4.3 Clinical Trials by Region, 2010 - 2017
4.4 Subjects Recruited by Region, 2010 - 2017
4.5 Clinical Trials by Year, 2010 - 2017
4.6 Subjects Recruited by Year, 2010 - 2017
4.7 Clinical Trials by Development Phase, 2010 - 2017
4.7.1 Clinical Trials by Phase
4.8 Subjects Recruited by Development Phase, 2010 - 2017
4.9 Clinical Trials by Status, 2010 - 2017
4.10 Subjects Recruited by Trial Status, 2010 - 2017
4.11 Clinical Trials by Sponsor Type, 2010 - 2017
4.12 Subjects Recruited by Sponsor Type, 2010 - 2017
4.13 Clinical Trials by Economy Type, 2010 - 2017
4.14 Clinical Trials and Subjects Recruited by Study Type, 2010 - 2017

5 Europe Malignant Glioma Clinical Trial Research Trends
5.1 Clinical Trials by Top Countries in Europe, 2010 - 2017
5.1.1 Europe, Clinical Trials by Country
5.2 Subjects Recruited by Top Countries in Europe, 2010 - 2017
5.2.1 Europe, Total Enrolment by Country
5.3 Europe, Clinical Trials by Year, 2010 - 2017
5.4 Europe, Clinical Trials by Development Phase, 2010 - 2017
5.5 Europe, Clinical Trials by Trial Status, 2010 - 2017
5.6 Europe, Clinical Trials by Sponsor Type, 2010 - 2017

6 North America Malignant Glioma Clinical Trial Research Trends
6.1 Clinical Trials by Top Countries in North America, 2010 - 2017
6.1.1 North America, Clinical Trials by Country
6.2 Subjects Recruited by Top Countries in North America, 2010 - 2017
6.2.1 North America, Total Enrolment by Country
6.3 North America, Clinical Trials by Year, 2010 - 2017
6.4 North America, Clinical Trials by Development Phase, 2010 - 2017
6.5 North America, Clinical Trials by Trial Status, 2010 - 2017
6.6 North America, Clinical Trials by Sponsor Type, 2010 - 2017

7 South and Central America Malignant Glioma Clinical Trial Research Trends

8 South East Asia Malignant Glioma Clinical Trial Research Trends

9 Western Pacific Malignant Glioma Clinical Trial Research Trends
9.1 Clinical Trials by Top Countries in Western Pacific, 2010 - 2017
9.1.1 Western Pacific, Clinical Trials by Country
9.2 Subjects Recruited by Top Countries in Western Pacific, 2010 - 2017
9.2.1 Western Pacific, Total Enrolment by Country
9.3 Western Pacific, Clinical Trials by Year, 2010 - 2017
9.4 Western Pacific, Clinical Trials by Development Phase, 2010 - 2017
9.5 Western Pacific, Clinical Trials by Trial Status, 2010 - 2017
9.6 Western Pacific, Clinical Trials by Sponsor Type, 2010 - 2017

10 Recent Clinical Trials - Snapshots
10.1 Malignant Glioma Trial Snapshots - 2018
10.2 Malignant Glioma Trial Snapshots - 2017
10.3 Malignant Glioma Trial Snapshots - 2016
10.4 Malignant Glioma Trial Snapshots - 2015
10.5 Malignant Glioma Trial Snapshots - 2014
10.6 Malignant Glioma Trial Snapshots - 2013
10.7 Malignant Glioma Trial Snapshots - 2012
10.8 Malignant Glioma Trial Snapshots - 2011
10.9 Malignant Glioma Trial Snapshots - 2010

11 Appendix
11.2 Sources and Research Methodology

1.1 List of Figures
Figure 1: Malignant Glioma - Average Enrolment by Country, 2010 - 2017
Figure 2: Malignant Glioma - Country wise Clinical Trials, 2010 - 2017
Figure 3: Malignant Glioma - Country wise Recruiting Sites, 2010 - 2017
Figure 4: Malignant Glioma - Country wise Subjects Recruited, 2010 - 2017
Figure 5: Global Malignant Glioma Clinical Trials Participation Share by Region, 2010 - 2017  
Figure 6: Global Malignant Glioma Subjects Recruited by Region, 2010 - 2017
Figure 7: Global Malignant Glioma Clinical Trials by Year, 2010 - 2017
Figure 8: Global Malignant Glioma Subjects Recruited by Year, 2010 - 2017
Figure 9: Global Malignant Glioma Trials by Phase, 2010 - 2017
Figure 10: Global Malignant Glioma - Subjects Recruited by Phase, 2010 - 2017
Figure 11: Global Malignant Glioma - Clinical Trials by Recruitment Status, 2010 - 2017
Figure 12: Global Malignant Glioma - Subjects Recruited by Trial Status, 2010 - 2017
Figure 13: Global Malignant Glioma - Clinical Trials by Sponsor Type, 2010 - 2017
Figure 14: Global Malignant Glioma - Subjects Recruited by Trial Status, 2010 - 2017
Figure 15: Global Malignant Glioma - Clinical Trials by Type of Economy, 2010 - 2017
Figure 16: Europe Malignant Glioma - Country wise Clinical Trials, 2010 - 2017
Figure 17: Europe Malignant Glioma - Country wise Subjects Recruited, 2010 - 2017
Figure 18: Europe Malignant Glioma - Year wise Clinical Trials, 2010 - 2017
Figure 19: Europe Malignant Glioma Trials by Phase, 2010 - 2017
Figure 20: Europe Malignant Glioma - Clinical Trials by Recruitment Status, 2010 - 2017
Figure 21: Europe Malignant Glioma - Clinical Trials by Sponsor Type, 2010 - 2017
Figure 22: North America Malignant Glioma - Country wise Clinical Trials, 2010 - 2017
Figure 23: North America Malignant Glioma - Country wise Subjects Recruited, 2010 - 2017
Figure 24: North America Malignant Glioma - Year wise Clinical Trials, 2010 - 2017
Figure 25: North America Malignant Glioma Trials by Phase, 2010 - 2017
Figure 26: North America Malignant Glioma - Clinical Trials by Recruitment Status, 2010 - 2017  
Figure 27: North America Malignant Glioma - Clinical Trials by Sponsor Type, 2010 - 2017
Figure 28: Western Pacific Malignant Glioma - Country wise Clinical Trials, 2010 - 2017
Figure 29: Western Pacific Malignant Glioma - Country wise Subjects Recruited, 2010 - 2017
Figure 30: Western Pacific Malignant Glioma - Year wise Clinical Trials, 2010 - 2017
Figure 31: Western Pacific Malignant Glioma Trials by Phase, 2010 - 2017
Figure 32: Western Pacific Malignant Glioma - Clinical Trials by Recruitment Status, 2010 - 2017  
Figure 33: Western Pacific Malignant Glioma - Clinical Trials by Sponsor Type, 2010 - 2017

1.2 List of Tables
Table 1: Malignant Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
Table 2: Malignant Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
Table 3: Malignant Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
Table 4: Malignant Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
Table 5: Malignant Glioma Pipeline Drug Profiles - Type, Class, Route of Administration, Mechanism of Action, Target
Table 6: Malignant Glioma - Region wise Clinical Trials, 2010 - 2017
Table 7: Malignant Glioma - Region wise Subjects Recruited, 2010 - 2017
Table 8: Global Malignant Glioma - Clinical Trials and Subjects by Trial Type, 2010 - 2017
Table 9: Malignant Glioma Trial Snapshots - 2018
Table 10: Malignant Glioma Trial Snapshots - 2018
Table 11: Malignant Glioma Trial Snapshots - 2018
Table 12: Malignant Glioma Trial Snapshots - 2017
Table 13: Malignant Glioma Trial Snapshots - 2017
Table 14: Malignant Glioma Trial Snapshots - 2017
Table 15: Malignant Glioma Trial Snapshots - 2017
Table 16: Malignant Glioma Trial Snapshots - 2017
Table 17: Malignant Glioma Trial Snapshots - 2017
Table 18: Malignant Glioma Trial Snapshots - 2017
Table 19: Malignant Glioma Trial Snapshots - 2017
Table 20: Malignant Glioma Trial Snapshots - 2017
Table 21: Malignant Glioma Trial Snapshots - 2017
Table 22: Malignant Glioma Trial Snapshots - 2017
Table 23: Malignant Glioma Trial Snapshots - 2017
Table 24: Malignant Glioma Trial Snapshots - 2017
Table 25: Malignant Glioma Trial Snapshots - 2017
Table 26: Malignant Glioma Trial Snapshots - 2017
Table 27: Malignant Glioma Trial Snapshots - 2017
Table 28: Malignant Glioma Trial Snapshots - 2017
Table 29: Malignant Glioma Trial Snapshots - 2017
Table 30: Malignant Glioma Trial Snapshots - 2017
Table 31: Malignant Glioma Trial Snapshots - 2017
Table 32: Malignant Glioma Trial Snapshots - 2017
Table 33: Malignant Glioma Trial Snapshots - 2017
Table 34: Malignant Glioma Trial Snapshots - 2017
Table 35: Malignant Glioma Trial Snapshots - 2017
Table 36: Malignant Glioma Trial Snapshots - 2016
Table 37: Malignant Glioma Trial Snapshots - 2016
Table 38: Malignant Glioma Trial Snapshots - 2016
Table 39: Malignant Glioma Trial Snapshots - 2016
Table 40: Malignant Glioma Trial Snapshots - 2016
Table 41: Malignant Glioma Trial Snapshots - 2016
Table 42: Malignant Glioma Trial Snapshots - 2016
Table 43: Malignant Glioma Trial Snapshots - 2016
Table 44: Malignant Glioma Trial Snapshots - 2016
Table 45: Malignant Glioma Trial Snapshots - 2016
Table 46: Malignant Glioma Trial Snapshots - 2016
Table 47: Malignant Glioma Trial Snapshots - 2016
Table 48: Malignant Glioma Trial Snapshots - 2016
Table 49: Malignant Glioma Trial Snapshots - 2016
Table 50: Malignant Glioma Trial Snapshots - 2016
Table 51: Malignant Glioma Trial Snapshots - 2016
Table 52: Malignant Glioma Trial Snapshots - 2016
Table 53: Malignant Glioma Trial Snapshots - 2016
Table 54: Malignant Glioma Trial Snapshots - 2016
Table 55: Malignant Glioma Trial Snapshots - 2015
Table 56: Malignant Glioma Trial Snapshots - 2015
Table 57: Malignant Glioma Trial Snapshots - 2015
Table 58: Malignant Glioma Trial Snapshots - 2015
Table 59: Malignant Glioma Trial Snapshots - 2015
Table 60: Malignant Glioma Trial Snapshots - 2015
Table 61: Malignant Glioma Trial Snapshots - 2015
Table 62: Malignant Glioma Trial Snapshots - 2015
Table 63: Malignant Glioma Trial Snapshots - 2015
Table 64: Malignant Glioma Trial Snapshots - 2015
Table 65: Malignant Glioma Trial Snapshots - 2015
Table 66: Malignant Glioma Trial Snapshots - 2015
Table 67: Malignant Glioma Trial Snapshots - 2015
Table 68: Malignant Glioma Trial Snapshots - 2015
Table 69: Malignant Glioma Trial Snapshots - 2015
Table 70: Malignant Glioma Trial Snapshots - 2015
Table 71: Malignant Glioma Trial Snapshots - 2015
Table 72: Malignant Glioma Trial Snapshots - 2015
Table 73: Malignant Glioma Trial Snapshots - 2015
Table 74: Malignant Glioma Trial Snapshots - 2015
Table 75: Malignant Glioma Trial Snapshots - 2015
Table 76: Malignant Glioma Trial Snapshots - 2014
Table 77: Malignant Glioma Trial Snapshots - 2014
Table 78: Malignant Glioma Trial Snapshots - 2014
Table 79: Malignant Glioma Trial Snapshots - 2014
Table 80: Malignant Glioma Trial Snapshots - 2014

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll